

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The ongoing Phase III DESTINY-BTC01 study compares trastuzumab deruxtecan (T-DXd) alone or in combination with which of the following agents to standard treatment as first-line therapy for patients with advanced HER2-expressing biliary tract cancer (BTC)?**
 - a. T-DM1
 - b. Trastuzumab/pertuzumab
 - c. Rilvegostomig**
 - d. Zanidatamab
- 2. The Phase III DESTINY-Gastric04 study of T-DXd versus ramucirumab/paclitaxel for previously treated HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma reported what finding at the interim analysis?**
 - a. Inferior overall survival (OS) outcomes with T-DXd
 - b. A nonsignificant trend toward OS improvement with T-DXd
 - c. A statistically significant improvement in OS with T-DXd**
 - d. No efficacy findings have been reported yet
- 3. The bispecific antibody zanidatamab binds to which of the following targets?**
 - a. HER2 and CD8
 - b. HER2 and HER3
 - c. HER2 and FGFR2
 - d. Two distinct HER2 domains**
- 4. Which of the following adverse events was most commonly observed in patients receiving zanidatamab for previously treated HER2-amplified BTC?**
 - a. Headache
 - b. Blurred vision
 - c. Dry mouth
 - d. Diarrhea**
- 5. What was the approximate objective response rate observed with T-DXd for patients with previously treated HER2 IHC 3+ advanced BTC in the Phase II DESTINY-PanTumor02 trial?**
 - a. 0%
 - b. 18%
 - c. 32%
 - d. 56%**